CHU de Grenoble

Running trials

• Not yet recruiting

  Vortosiran for VTE Prevention

  NCT07850453· Phase 2· Source

• Not yet recruiting

  AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

  NCT07604727· Source

• Recruiting

  Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

  NCT07570589· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Source

• Not yet recruiting

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· Phase 2· Source

• Recruiting

  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

  NCT07122089· Phase 2· Source

• Recruiting

  Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

  NCT07243483· Source

• Not yet recruiting

  Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors

  NCT06798532· Source

• Recruiting

  Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

  NCT07072988· Phase 4· Source

• Recruiting

  Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis

  NCT06386107· Source

• Recruiting

  KONO-S Anastomosis Compared to Conventional Ileocolonic Anastomosis to Reduce Recurrence in Crohn's Disease

  NCT05974358· Source

• Recruiting

  Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves

  NCT06181357· Source

• Recruiting

  EWALL-PH OBSERVARTORY 2022

  NCT07684131· Source

• Recruiting

  Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

  NCT05983991· Source

• Active, not recruiting

  Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

  NCT05999604· Phase 3· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Source

• Recruiting

  Characteristics and Outcomes of Patients Admitted to ICU for a Severe Acute Exacerbation of COPD.

  NCT06257329· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Source

• Active, not recruiting

  AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

  NCT04881032· Phase 1/2· Source

• Active, not recruiting

  Chronic Pain and Hemophilia

  NCT05202951· Source

• Active, not recruiting

  Observatory of Patients With Haemophilia B Treated by IdElvion®

  NCT05086575· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Source

• Active, not recruiting

  Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

  NCT04070443· Phase 2· Source

• Recruiting

  French Registry for Monitoring Pregnancies for Multiple Sclerosis

  NCT03900221· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of TLD in Patients with COPD

  NCT03639051· Source

• Active, not recruiting

  Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

  NCT03981003· Source

• Active, not recruiting

  IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

  NCT03744390· Phase 2· Source

• Active, not recruiting

  OFSEP High Definition Cohort

  NCT03603457· Source

• Active, not recruiting

  A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

  NCT03223961· Phase 3· Source

• Recruiting

  French National Database of Rare Dermatological Cancers

  NCT03210935· Source

• Enrolling by invitation

  Juvenile Inflammatory Rheumatism (JIR) Cohorte

  NCT02377245· Source

• Recruiting

  Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

  NCT02828202· Source

• Recruiting

  COsegregation of VARiants in Panel of Genes

  NCT01689584· Source

• Active, not recruiting

  Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

  NCT02870907· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Acute myeloid leukemia2 recruiting
• COPD2 recruiting
• Myasthenia gravis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Crohn's disease1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

  NCT06080399· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

  NCT04827719· Phase 2· Source

• Completed

  Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

  NCT04703686· Phase 2· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· Source

• Terminated

  Interest of the Smartphone Application "MonCœur" in the Follow-up of Patients With Heart Failure

  NCT04198779· Source

• Terminated

  Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

  NCT03765541· Phase 3· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Source

• Completed

  Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits

  NCT04111211· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· Source

• Completed

  Is Caffeine an Environmental Modifier in Huntington's Disease?

  NCT03034122· Source

• Completed

  Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV

  NCT02835638· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Source

• Terminated

  Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone

  NCT02806258· Phase 1/2· Source

• Terminated

  Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension

  NCT02525926· Source

• Completed

  French Registry of First-line Treatment of Acute Promyelocytic Leukemia

  NCT02938858· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

• Completed

  Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

  NCT01868269· Phase 3· Source